

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications (Non-Prescriptive Items)</i>	<i>Date of Authorisation</i>
0101/5047R	Sandoz Products Limited	Syntopressin Nasal Spray	Lypressin 50-00 iu	Not applicable. POM	15th August 1991
0109/0190	Roussel Laboratories Limited	Uclaprim Paediatric Suspension	Each 5 ml of suspension contains: Sulphamethoxazole EP 200 mg Trimethoprim EP 40 mg	POM	13th December 1991
0109/0227	Roussel Laboratories Limited	Surgam SA Tablet 300 mg	Tiaprofenic Acid Micronised* HSE 300 mg * As Surgam SA Pellets	POM	28th February 1992
0109/0228	Roussel Laboratories Limited	Surgam SA Tablet 600 mg	Tiaprofenic Acid Micronised* HSE 600 mg * As Surgam SA Pellets	POM	28th February 1992
0109/0231	Roussel Laboratories Limited	Orelox Tablets	Cefpodoxime Proxetil HSE 130-45 mg (Equivalent to 100 mg Cefpodoxime)	POM	6th January 1992
0111/0002	Dental Health Promotion Ltd	Fluor-a-day Tablets 1 mg	Sodium Fluoride BP 1-00 mg	PM	28th January 1991
0113/0139	Fisons plc—Pharmaceutical Division	Rynacrom 4% Nasal Spray	Sodium Cromoglycate BP 4-00% w/w	Rynacrom Nasal Spray is indicated for the preventive treatment of allergic rhinitis (seasonal and perennial). <i>Route of Administration:</i> Nasal Spray PM	8th March 1991
0113/0145	Fisons plc t/a Fisons Consumer Health	Vapex Inhalant	Menthol BP 18-00% w/w	For relief from colds and nasal catarrh. GSL	15th February 1990
0113/0154	Fisons plc—Pharmaceutical Division	Antabuse Tablets 200 mg	Disulfiram BP 200-00 mg	POM	8th January 1992
0113/5054R	Fisons plc—Pharmaceutical Division	Dextraven 150 6% in 5% Dextrose	Dextran of weight average molecular weight—150,000 6-00% w/v	Not applicable. POM	30th October 1991
0113/5060R	Fisons plc—Pharmaceutical Division	Lomodex 70 in 5% Dextrose	Dextran of weight average molecular weight—70,000 6-00% w/v	Not applicable. POM	30th October 1991
0113/5061R	Fisons plc—Pharmaceutical Division	Lomodex 70 in 0-9% Sodium Chloride	Dextran of weight average molecular weight—70,000 6-00% w/v	Not applicable. POM	21st October 1991
0113/5083R	Fisons plc—Pharmaceutical Division	Dextran Powder 40	Dextran 40 100-00% w/w	Not applicable. The material is an ingredient in Dextran Injection	20th February 1991
0113/5084R	Fisons plc—Pharmaceutical Division	Dextran Powder 60	Dextran 60 100-00% w/w	Not applicable. The material is an ingredient in Dextran Injection	20th February 1991
0113/5085R	Fisons Plc—Pharmaceutical Division	Dextran Powder 70	Dextran 70 100-00% w/w	Not Applicable. The material is an ingredient in Dextran Injection	20th February 1991
0113/5086R	Fisons Plc—Pharmaceutical Division	Dextran Powder 75	Dextran 75 100-00% w/w	Not Applicable. The material is an ingredient in Dextran Injection	20th February 1991
0113/5087R	Fisons Plc—Pharmaceutical Division	Dextran Powder 110	Dextran 110 100-00% w/w	Not Applicable. The material is an ingredient in Dextran Injection	20th February 1991
0113/5088R	Fisons Plc—Pharmaceutical Division	Dextran Powder 150	Dextran 150 100-00% w/w	Not Applicable. The material is an ingredient in Dextran Injection	20th February 1991
0116/0218	Baxter Healthcare Limited	Sottran	Potassium Citrate EP 0-86% w/v Sodium Citrate EP 0-82% w/v Mannitol BP 3-8% w/v Magnesium Sulphate EP 1-0% w/v	POM	9th September 1991
0125/0202	Bristol-Myers Company Limited	Enkaid 25 mg Capsules	Encaidine Hydrochloride 25-0 mg Equivalent to Encaidine 22-65 mg	POM	19th December 1990
0125/0203	Bristol-Myers Company Limited	Enkaid 50 mg Capsules	Encaidine Hydrochloride 50-0 mg Equivalent to Encaidine 45-3 mg	POM	19th December 1990